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Abstract
Concurrent radiochemotherapy (RCT) is the treatment of choice for patients with locally advanced non–small-cell lung
cancer (NSCLC). Two meta-analyses were inconclusive in an attempt to define the optimal concurrent RCT scheme.
Besides efficacy, treatment toxicity will influence the appointed treatment of choice. A systematic review of the
literature was performed to record the early and late toxicities, as well as overall survival, of concurrent RCT regimens
in patients with NSCLC. The databases of PubMed, Ovid, Medline, and the Cochrane Library were searched for
articles on concurrent RCT published between January 1992 and December 2009. Publications of phase II and phase
III trials with  50 patients per treatment arm were selected. Patient characteristics, chemotherapy regimen (mono-
or polychemotherapy, high or low dose) and radiotherapy scheme, acute and late toxicity, and overall survival data
were compared. Seventeen articles were selected: 12 studies with cisplatin-containing regimens and 5 studies using
carboplatin. A total of 13 series with mono- or polychemotherapy schedules—as single dose or double or triple
high-dose or daily cisplatin-containing ( 30 mg/m2/wk) chemotherapy were found. Acute esophagitis grade 3 was
observed in up to 18% of the patients. High-dose cisplatin regimens resulted in more frequent and severe hemato-
logic toxicity, nausea, and vomiting than did other schemes. The toxicity profile was more favorable in low-dose
chemotherapy schedules. From phase II and III trials published between 1992 and 2010, it can be concluded that
concurrent RCT with monochemotherapy consisting of daily cisplatin results in favorable acute and late toxicity
compared with concurrent RCT with single high-dose chemotherapy, doublets, or triplets.
Clinical Lung Cancer, Vol. 14, No. 5, 481-7 © 2013 Elsevier Inc. All rights reserved.
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In the past 2 decades, many trials of combined-modality treatment
in patients with locally advanced (stage III) non–small cell lung can-
cer (NSCLC) have been published. Results of sequential and con-
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http://dx.doi.org/10.1016/j.cllc.2013.03.002current combinations of radiotherapy and chemotherapy were pub-
lished as single reports as well as meta-analyses.
The first study reporting improved survival for patients with stage
III NSCLC after treatment with sequential radiochemotherapy
(RCT) was in 1990 by Dillman et al.1 This approach became the
tandard treatment after the meta-analysis was published by the
on-Small Cell Lung Cancer Collaborative Group in 1995.2 Induc-
tion chemotherapy added to radiotherapy yielded 4% 2-year and 2%
5-year survival benefit provided that the chemotherapy scheme con-
tained cisplatin. This improvement was attributed to the cytotoxic
effect on subclinical distant metastases. This effect was observed in a
French trial3 as well; however, patients with adenocarcinoma were
ot included in this study.
In the same period, a different schedule of combining radio- and
hemotherapy was introduced: the concurrent RCT. The European
rganisation for Research and Treatment of Cancer (EORTC)8844 study indicated that concurrent chemotherapy works as a
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482radiosensitizer: 6 mg/m2 cisplatin daily preceding each fraction of
adiotherapy improved local progression-free survival compared
ith radiotherapy alone: at 1 year 59% vs. 41% and at 2 years 31%
s. 19%.4 Improved local control contributed to increased overall
survival: 54% vs. 46%, 26% vs. 13% and 16% vs. 2% at 1, 2, and 3
years, respectively. Late toxicity was not increased. There was no
difference in distant metastases rates. The same radiotherapy sched-
ule concurrent with a weekly dose of 30 mg/m2 cisplatin did not yield
statistically significant survival difference, but a trend in increased
urvival suggested that the way cisplatin is combined with the radia-
ion might be crucial. A meta-analysis in 2006 of concurrent RCT vs.
adiotherapy alone revealed a gain in overall 2- and 5-year survival
ates similar to those of the sequential combination.5 Prospective
linical trials randomizing between sequential and concurrent RCT
ere subsequently performed.6-10 A meta-analysis of these trials pub-
ished in 2010 showed that concurrent RCT is superior to sequential
CT, with improved 2-, 3- and 5-year overall survival rates of 35.6%
s. 30.3%, 23.8% vs. 18.1% and 15.1% vs. 10.6%, respectively (P
.004).11 The most important reported acute toxicity of concurrent
CT was esophagitis  grade 3 in up to 18% of the patients. Re-
orted hematologic toxicities were dependent on the type of concur-
ent chemotherapy: polychemotherapy vs. daily or weekly monoche-
otherapy. Exact data on late toxicities other than esophagitis were
issing in most trials.
Thus far it is not clear which chemotherapy regimen combined
ith radiotherapy is superior in terms of survival and toxicity
rofile. Besides the EORTC 08844 study, prospective random-
zed trials comparing different concurrent RCT regimens are
acking. We therefore performed a review of the literature to
ompare acute and late toxicities and to conclude which treat-
ent should preferably be offered to patients with locally ad-
anced nonmetastasized NSCLC.
Review Design
Search Strategy
A systematic search was performed in the databases of PubMed,
Ovid, Embase, and the Cochrane Library for publications be-
tween 1992 and January 2010 reporting on studies of patients
with NSCLC treated with concurrent RCT (Table 1). Articles
had to be published in print in English. An exploratory search
yielded 1 unique relevant record in PubMed that could not be
retrieved by the final comprehensive search resulting from the fact
that the aspect of concomitance was not captured in the metadata
of this record by the search strategy. Adaptation of the search
strategy to include this record retrieved only other irrelevant re-
cords and was therefore abandoned.
Selection Criteria
We selected those articles that studied concurrent RCT for pa-
tients treated in phase II and phase III studies and included at least 50
patients per treatment arm. Treatment arms that included surgery,
consolidation and/or induction chemotherapy, or hyperfractionation
schemes were excluded to rule out factors other than the concurrent
chemotherapy regimen influencing toxicity and treatment results.
Radiotherapy had to be of radical or curative intent. Radical radio-
therapy was defined as a minimum total dose of 48 Gy in daily 2-Gy
fractions or its radiobiological equivalent. Selected data were number of
Clinical Lung Cancer September 2013patients treated, performance score (World Health Organization
[WHO], Eastern Cooperative Oncology Group [ECOG], or Karnof-
sky), clinical TNM stage, histologic type, radiotherapy dose, chemother-
apy type and dose, treatment schedule, acute and late side effects (WHO
grade 3-5), local progression-free and overall survival, and year of
publication.
Two of the authors (SW and CK) performed the literature search
and independently reviewed and screened a total of 3016 articles;
after reading the titles, 483 were selected for evaluation of the abstracts
if available, leaving 135 that were studied in detail. The final result was
17 articles, including 1 from a screened reference list, representing 18
series, which were analyzed and are summarized here. The series that
were selected are part of several different trial designs of RCT vs. radio-
therapy alone, sequential vs. concurrent RCT, concurrent RCT vs. con-
current RCT after induction chemotherapy, and so on.
Radiotherapy and Chemotherapy
Regimens
Radiotherapy doses prescribed varied between 45 and 70.2 Gy, and
the dose per fraction varied between 1.8 and 3.0 Gy. There were a total
Table 1 Systematic Search Strategy
PubMed (the search in The Cochrane Library was adapted from the PubMed
search)
December 2009
(Non-Small-Cell Lung Carcinomas OR Non-Small-Cell Lung Cancer OR
nsclc[ttw]) AND ((adjuvant chemotherapy AND (radiation OR radiother* OR
radiochem*)) OR concurrent radio chemotherap* OR concurrent
radiochemotherap* OR concurrent chemoradiotherap* OR concomitant radio
chemotherap* OR concomitant chemo radiotherap* OR concomitant
radiochemotherap* OR concomitant chemoradiotherap* OR ((“concurrent
radiation therapy” OR “concomitant radiation therapy”) AND (chemorad* OR
chemotherap*)) OR ((radiotherapy AND chemotherapy) AND (concurrent or
concomitant or “combined modality”)))
Embase 1980 until Present, OVIDSP
December 2009
1. lung non small cell cancer.mp.
2. non small cell lung carcinoma?.ab,ti.
3. nsclc.ab,ti.
4. or/1-3
5. (concurrent radio adj1 chemotherap$).ab,ti.
6. concurrent radiochemotherap$.ab,ti.
7. concurrent chemoradiotherap$.ab,ti.
8. (concomitant radio adj1 chemotherap$).ab,ti.
9. concomitant radiochemotherap$.ab,ti.
10. concomitant chemoradiotherap$.ab,ti.
11. cancer radiotherapy/ and cancer chemotherapy/ and (concurrent or
concomitant or “combined modaliy”).mp.
12. (concomitant chemo adj1 radiotherap$).ab,ti.
13. (((concurrent or concomitant) adj2 radiation therapy) and chemo*).mp.
14. or/5-13
15. 4 and 14
16. limit 15 to Embaseof 4 split-course series and 6 conventional series (Tables 2 and 3). The
1
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Caro C. Koning et alradiotherapy fractionation schemes were recalculated to a radiobio-
logically equivalent dose (isoeffective dose display [EQD2] / 
0) to compare the applied tumor doses. The total EQD2 tumor
oses varied from 48.6 to 70 Gy.
As can be seen in Table 2, the chemotherapy consisted of carbo-
Table 2 Trial Design of Concurrent RCT Phase II and III Study-
Reference Phase No. of Patients
Ball et al, 199912 III 54
Groen et al, 200413 III 82
Isakovic´-Vidovic´ et al, 200214 III 67
Lau et al, 199815 II 60
C
Vokes et al, 200716 III 182
Abbreviation: AUC area under the curve.
Table 3 Treatment Schedules of NSCLC Patients on Concurren
With Cisplatin
Reference Phase No. of Patients
Belderbos et al, 20076 III 80
Blanke et al, 199517 III 104
Cakir et al, 200418 III 88
Furuse et al, 19999 III 156
Furuse et al, 199519 II 51
Ichinose et al, 200420 II 70
Kim et al, 200521 II 135
Pradier et al, 200522 II 56
Schaake-Koning et al,
19924 (d) III 102
Schaake-Koning et al,
19924 (wk) III 98
Schild et al, 200223 III 117
Trovó et al, 199225 II 94
Trovó et al, 199224 III 85
Abbreviations: d daily cisplatin; EQD2 isoeffective dose display; wk weekly cisplatin.latin in 5 articles.12-16 Carboplatin was administered continuouslyntravenously in the series reported by Groen et al.13 Isakovic´-
Vidovic´ used the same dose as a bolus.14 High-dose carboplatin was
part of a polychemotherapy schedule in 2 articles and a monoche-
motherapy schedule in 3 articles. The concurrent carboplatin regi-
mens selected revealed overall survival rates similar to those of radio-
for NSCLC Patients; Combinations With Carboplatin
Chemotherapy Radiotherapy Dose EQD2 (Gy)
latin 70 mg/m2/d days 1-5, days
29-33 60
oplatin 20 mg/m2/d days 1-42 60
platin 20 mg/m2/d before every
radiation fraction 58.5 (split 14 d)
atin 200 mg/m2 days 1, 3, 29, 31
oposide 50 mg/m2 days 1-4,
days 29-32
60
litaxel 50 mg/m2, carboplatin
AUC 2, weekly 7 wks 66
Used in Phase II and Phase III Study Arms; Combinations
Chemotherapy Radiotherapy Dose EQD2 (Gy)
latin 6 mg/m2, 1-2 h before
every radiation fraction 70
tin 70 mg/m2, every 3 wk,3 65
platin 20 mg/m2, 1 h before
ation fraction d 1-5 of wk 2,
wk 6
64
splatin 80 mg/m2 d 1, 29;
sine 3 mg/m2 d 1, 8, 29, 36,
itomycin 8 mg/m2 d 1, 29
56 (split 10 d)
platin 100 mg/m2 d 1, 29;
sine 3 mg/m2 d 1, 8, 29, 36;
itomycin 8 mg/m2 d 1, 29
56 (split 10 d)
fur 400 mg/m2 d 1-14, d 29-
uracil 896 mg/m2 d 1-14, d
2; cisplatin 80 mg/m2 d 8,6
60
itaxel 40 mg/m2; cisplatin 20
mg/m2, 1/wk, 8 wk 68.8
tin 6 mg/m2 5 d in wk 1-2 and
5-6 60
platin 6 mg/m2 before every
radiation fraction 58.5 (split 3-4 wk)
platin 30 mg/m2 d 1 every
radiotherapy week 58.5 (split 3-4 wk)
side 100 mg/m2; cisplatin 30
mg/m2 d 1-3, d 28-30 60
tin 6 mg/m2 1 h before every
radiation fraction 48.6
tin 6 mg/m2 1 h before every
radiation fraction 48.6Arms
Carbop
Carb
Carbo
arbopl
Et
Pact RCT
Cisp
Cispla
Cis
radi
Ci
vinde
m
Cis
vinde
m
Tega
42;
29-4
Pacl
Cispla
Cis
Cis
Etopo
Cispla
Cisplatherapy-alone regimens.12-14 In 12 articles containing 13 series, the
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484chemotherapy regimen contained cisplatin.4,6,9,17-25 Cisplatin was
art of polychemotherapy courses in 5 trials; in all these schedules,
igh-dose cisplatin ( 30 mg/wk) was prescribed. In the cases in
hich single-agent cisplatin was used, it was prescribed in a high-
ose regimen in 2 series and as a low-dose ( 30 mg/wk) daily
egimen in 6 series (Tables 3 and 4).
Toxicity
Acute toxicity consisting of esophagitis grade 3 was mentioned in
almost all reports on concurrent RCT. Its incidence varied from 1% up
to 18% of patients. In 3 studies, the reported acute esophagitis grades
3 were similar: 16%, 17% and 18% (Table 5). Nausea and vomiting
were encountered especially in the early trials. When high-dose cisplatin
was given, nausea and vomiting was greater (at least 4 trials with16%)
than when applied in daily low-dose schedules. Hematologic toxicities,
such as anemia, leukocytopenia, and thrombocytopenia, were more fre-
quently observed in the high-dose chemotherapy schedules. In 7 studies,
grade 5 complications (cardiomyopathy, massive hemoptysis, radiation
pneumonitis, respiratory failure) were reported in up to 3% of the pa-
Table 4 Patient Characteristics of NSCLC Patients on Concurre
With Cisplatin
Reference ChemotherapyScheme
No. o
Patien
Belderbos et al, 20076 ML 80
Pradier et al, 200522 ML 56
Schaake-Koning et al, 19924 (d) ML 102
Schaake-Koning et al, 19924 (wk) ML 98
Trovó et al, 199225 ML 94
Trovó et al, 199224 ML 85
Blanke et al, 199517 MH 104
Cakir et al, 200418 MH 88
Furuse et al, 19999 PH 156
Furuse et al, 199519 PH 51
Ichinose et al, 200420 PH 70
Kim et al, 200521 PH 135
Schild et al, 200223 PH 117
Abbreviations: d daily cisplatin; ECOG Eastern Cooperative Oncology Group; H high dose;
orld Health Organization; wk weekly cisplatin.tients. Late toxicity was not reported systematically in most studies. The
Clinical Lung Cancer September 2013incidence of acute esophagitis  grades 3 in chemotherapy regimens
containing carboplatin varied from 9% up to 32%. Hematologic toxic-
ity rates in carboplatin regimens were similar to those using high-dose
cisplatin (Table 6). In the article by Ball et al., 3 of 54 patients experi-
enced late grade 3 to 4 esophagitis.12 In the low-dose cisplatin studies,
late esophagitis grade 3 to 4 was reported in 5% of the patients. The
overall survival in all studies (Table 7) ranged from 13% to 38.5% at 2
years and from 7% to 29.2% at 3 years. The median survival varied from
10 to 17 months.
Discussion
After analyzing the toxicity profiles of 17 selected articles on
NSCLC patients treated with concurrent RCT, it was concluded
that concurrent daily gifts of cisplatin monochemotherapy causes less
severe toxicity compared to polychemotherapy or mono high-dose
cisplatin. In 12 of the articles, cisplatin-containing chemotherapy
was applied; in 8 studies, it was administered as a single agent and in
4 studies as part of a polychemotherapy regimen. In 7 series, high-
dose cisplatin was administered and in 6 series, daily or weekly low-
T Used in Phase II and Phase III Study Arms; Combinations
Median Age
(y)
Performance
Status
Median Follow-Up
(mo)
62 WHO 0, 44%;WHO 1, 56% 39
64 KPS 50-70, 23%;KPS 80-100, 77%
61
WHO 0, 39%;
WHO 1, 56%;
WHO 2, 5%
 22
61
WHO 0, 31%;
WHO 1, 62%;
WHO 2, 7%
 22
62 KPS median 80%(60%-100%)  48
62 KPS median 80%(60%-100%)
63 KPS 70%-100% 52
60 ECOG 1, 65%;ECOG 2, 35%
64
WHO 0, 25%;
WHO 1, 69%;
WHO 2, 6%
60
59
ECOG 0, 5%;
ECOG 1, 74%;
ECOG 2, 21%
33.5
61 WHO 0, 64%;WHO 1, 36% 33
60
ECOG 0, 7%;
ECOG 1, 86%;
ECOG 2, 7%
24
Unknown ECOG 0, 49%;ECOG 1, 51% 43
ily low dose; KPS Karnofsky score; Mmonochemotherapy; P polychemotherapy; WHOnt RC
f
tsdose cisplatin was prescribed. Carboplatin-containing regimens
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Caro C. Koning et aladded to radiotherapy did not result in improved progression-free
and overall survival. This is in line with the findings of van de Vaart
et al, indicating that the radiosensitizing effect of cisplatin derivatives
is less compared with cisplatin itself.26,27 Daily administration of
isplatin monochemotherapy did not yield inferior results in terms of
verall and progression-free survival; however, selection criteria were
ifferent among the trials. In the meta-analysis of Aupérin et al,11
there was no difference in the distant metastases rates between the
concurrent and the sequential RCT arms. In addition, the daily ad-
ministration of cisplatin, monochemotherapy caused less severe tox-
icity. Since polychemotherapy and high-dose chemotherapy regi-
mens have not been randomized against single-agent daily cisplatin,
it is currently impossible to select the optimal concurrent RCT
combination.
Hematologic side effects were rarely observed in the low-dose cis-
Table 5 Survival Results of NSCLC Patients on Concurrent RCT
Cisplatin
Chemotherapy
Scheme
Nausea/
Vomiting
(%)
Esophag
(%)
Belderbos et al, 20076 ML 6 17
Pradier et al, 200522 ML — —
Schaake-Koning et al,
19924 (d) ML 24 4
Schaake-Koning et al,
19924 (wk) ML 21 1
Trovó et al, 199225 ML 5 2
Trovó et al, 199224 ML 1 16
Blanke et al, 199517 MH 5 3
Cakir and Egehan,a 200418 MH 24 (2) 10
Furuse et al, 19999 PH 23 2.6
Furuse et al, 199519 PH 16 6
Ichinose et al, 200420 PH 4 3
Kim et al, 200521 PH — 4
Schild et al,c 200223 PH 26 18 (2)
Abbreviations: d daily cisplatin; H high dose; L daily low dose; M monochemotherap
a Exact toxicity grade unknown, probably grade 2 (grade 3).
b 19% hematologic toxicity not further specified.
c Numbers in parentheses represent grade 4 toxicity.
Table 6 Toxicity Results > Grade 3 of NSCLC Patients on Con
Combinations With Carboplatin
Reference Phase No. ofPatients
Nausea/Vomiting
(%)
Eso
Ball et al, 199912 III 54 —
Groen et al, 200413 III 82 3%
Isakovic´-Vidovic´ et al,
200214 III 67 —
Lau et al, 199815 II 60 3 (5)
Vokes et al, 200716 III 182 —platin groups, avoiding risks of infections during a neutrocytopenicperiod. Nausea was high in the pioneer studies but decreased after the
introduction of 5 hydroxytryptamine type 3 receptor antagonists in
the early 1990s. With high-dose chemotherapy schedules, more tox-
icity was observed: hematologic toxicity and nausea and vomiting
were reported in higher percentages (at least 4 trials with  16%).
hen the daily or weekly low-dose cisplatin schemes were used, the
ausea and vomiting complaints were mild, and cisplatin adminis-
ration was not frequently reduced. When high-dose cisplatin is con-
urrently administered with radiotherapy to patients with head and
eck cancer, hearing loss is more frequently encountered when com-
ared with the low-dose schedule.28 To the best of our knowledge,
this ototoxicity has never been studied in patients with locally ad-
vanced NSCLC, but arguments are lacking about why this side effect
should be different from that found for patients with head and neck
cancer. To avoid excessive severe (mucosal) toxicity, several clinicians
d in Phase II and Phase III Study Arms; Combinations With
Leukopenia
(%)
Anemia
(%)
Thrombocytopenia
(%)
Grade 5 Toxicity
(%)
3 0 — 1
5 — — 0
3 — 0 0
1 — 0 2
— 0 — 1
0 0 —
5 — — 2
15 (3) 8 — —
98.7 10.3 52.6 —
95 28 45 2
16 6 1 0
b b b 0.7
38 (40) — 26 (3) 3
polychemotherapy; wk weekly cisplatin.
nt RCT Used in Phase II and Phase III Study Arms;
itis Leukopenia
(%)
Anemia
(%)
Thrombocytopenia
(%)
Grade 5
Toxicity (%)
— 0 6 0
11 3 11 —
3 3 1.5 —
50 5 23 0
62 5 36 —Use
itis
y; Pcurre
phag
(%)
21
9
10
16recently started with low-dose chemotherapy in vulnerable patients
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486with head and neck cancer.29,30 Their preliminary reports are prom-
sing. A phase I study has been reported with low-dose paclitaxel
dministered as a radiosensitizer for patients with NSCLC.31
In this present overview, 1 study applied high-dose radiation of 70
Gy.6 This 70-Gy regimen was tested in a phase II trial that had
evealed the safety of this fractionation scheme in case a restriction
or the length of the irradiated esophagus was met: 18 cm up to 40
y and  12 cm in the boost volume up to 66 Gy.32 One might
rgue that patients with NSCLC with low tumor volumes were se-
ected in this trial.
Most patients with lung cancer and a smoking history are at high risk
or heart and vessel diseases as well as chronic pulmonary diseases such as
mphysema and chronic obstructive bronchitis. In general, the highest
ncidence of NSCLC is observed in patients older than 65 years. As a
onsequence, a considerable percentage of patients with newly diag-
osed NSCLC is frail and unfit for concurrent RCT treatments. More
han half of patients with stage III lung cancer were theoretically not
ligible for concurrent RCT in a population-based study.33 Less toxic
lternatives are needed for these patients. Uitterhoeve et al reported ex-
ellent tolerance of concurrent RCT with daily cisplatin for a group of
lderly patients, with good survival data (1-, 2-, and 5-year overall sur-
ival of 60%, 34%, and 24%, respectively).34
A favorable toxicity profile makes low-dose concurrent RCT
schedules suitable for combinations with targeted agents such as vas-
cular epithelial growth factor antibodies, antifolates, and epidermal
growth factor receptor antibodies. This is important because the
addition of these new drugs to concurrent RCT with full-dose che-
motherapy could increase toxicity.35
The feasibility of adding the epidermal growth factor receptor inhib-
Table 7 Toxicity Results > Grade 3 of NSCLC Patients on Con
Combinations With Cisplatin
Reference Phase ChemotherapyScheme
No. of
Patients
Belderbos et al, 20076 III ML 80
Pradier et al, 200522 II ML 56
Schaake-Koning et al,
19924 (d) III ML 102
Schaake-Koning et al,
19924 (wk) III ML 98
Trovó et al, 199225 II ML 94
Trovó et al, 199224 III ML 85
Blanke et al, 199517 III MH 104
Cakir et al, 200418 III MH 88
Furuse et al, 19999 III PH 156
Furuse et al, 199519 II PH 51
Ichinose et al, 200420 II PH 70
Kim et al, 200521 II PH 135
Schild et al, 200223 III PH 117
Abbreviations: d daily cisplatin; H high-dose; L daily low-dose; Mmonochemotherapy;
a Survival without local recurrence.itor cetuximab to concurrent chemoradiotherapy (CRT) with daily cis-
Clinical Lung Cancer September 2013platin has been reported for patients with NSCLC.36 A study adding the
ntifolate pemetrexed to concurrent RCT is under way.37 Gefinitib
added to CRT did not yield improved survival in a phase II trial.38
Our review has some limitations because series of at least 50 patients
treated in a phase II or III trial were selected. This selection was made to
provide robust data on toxicity but leaves out numerous studies with
smaller numbers of patients. Studies on induction and/or consolidation
therapy added to concurrent RCT were not included to draw clear con-
clusions on the preferred concurrent treatment schedule. Moreover, un-
til now these types of therapies did not yield further improved treatment
outcome.16,39 Recently, 2 articles were published on concurrent CRT
ith excellent treatment results at a cost of severe toxicity.40,41 In the
meta-analysis on sequential vs. concurrent RCT,11 the staging examina-
tions were less sensitive, so a significant number of patients (15% on
estimation) probably had stage IV disease. In this patient group, how-
ever, an improved locoregional control in the concurrently treated pa-
tients did result in an increased overall survival. The patients with
NSCLC selected today for RCT are more rigorously staged using fluo-
rine-18 fluorodeoxyglucose positron emission tomography, magnetic
resonance imaging of the cerebrum, endoesophageal ultrasonography,
and/or endobronchial ultrasonography. It is to be expected that a current
improved locoregional control rate result will have a more profound
influence on overall survival. Compared with current radiotherapy tech-
niques and fractionation schedules, the radiotherapy administered was
suboptimal in many trials. There were 4 split-course radiotherapy sched-
ules, and the radiotherapy dose was  60 Gy (EQD2) in 6 trials. In
addition, new radiotherapy techniques such as intensity-modulated ra-
diotherapy have evolved, allowing higher radiation doses in the tumor-
positive areas while avoiding high doses in the surrounding tissues. The
nt RCT Used in Phase II and Phase III Study Arms;
edium
S (mo)
2 Years
OS (%)
3 Years
OS (%)
5 Years
OS (%) PFS
16.5 38.5 29.2 — 36.6% at 1 y
14 34 16 — —
13 26 16 — 59% at 1 y, 31%at 2 ya
12 19 13 — 42% at 1y, 30%at 2 ya
12 24.4 10 — —
10 13 7 — —
10.8 18 9 5 —
10 18 10 — 10% at 3 y
16.5 34.6 22.3 15.8 —
16 36.7 23.1 — —
16.5 33 24 — —
17 37 Unknown — 36% at 1 y, 18%at 2 y
17 37 23 13 25% at 2 y, 23%at 2 y
verall survival; P polychemotherapy; PFS progression-free survival; wkweekly cisplatin.curre
M
Ofrequently applied image-guided radiotherapy allows even more precise
12
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
Caro C. Koning et aldose delivery and is expected to further improve treatment outcome in
patients with NSCLC. As long as subclinical distant metastases cannot
yet be controlled efficiently, our main focus should be on improving
survival by better locoregional tumor control.42
Conclusion
A systematic review of the literature was performed to compare
acute and late toxicity in patients with NSCLC treated with concur-
rent CRT. It can be concluded that concurrent RCT regimens with
low-dose daily cisplatin yield a favorable toxicity profile compared
with high-dose mono- or polychemotherapy. Concurrent RCT with
low-dose cisplatin and high-dose radiotherapy can be considered the
preferred treatment.
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